United States & Pfizer
10 shared events · Importance 7 · Last updated Jul 02, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
United States: The United States is the primary market for the Lyme disease vaccine, with a significant and expanding incidence of the disease. Regulatory approval within the United States, particularly from the United States — Food and Drug Administration, is crucial for the vaccine's availability.
Pfizer: Pfizer is a pharmaceutical company developing a new Lyme disease vaccine, which has shown 70-75% effectiveness in late-stage studies. The company plans to seek regulatory approval, which could significantly boost its market position in infectious disease prevention.
Apr 30, 2026 · 20 articles
Tech
United States: The United States Food and Drug Administration approved the RSVpreF vaccine in 2023, and the United States — Centers for Disease Control and Prevention provides statistics on RSV hospitalizations, highlighting the public health relevance of the vaccine within the nation.
Pfizer: Pfizer manufactures the RSVpreF vaccine, which has shown significant effectiveness in preventing RSV-associated hospitalizations in infants. This positive real-world data validates their product and could lead to increased sales and market share in the vaccine segment.
Jun 05, 2026 · 7 articles
Regulatory
Pfizer: Pfizer previously agreed to lower the cost of prescription drugs for United States — Medicaid following an executive order, setting a precedent for the current deal with Eli Lilly and Company and Novo Nordisk.
Nov 06, 2025 · 6 articles
Regulatory
Pfizer: Pfizer had previously struck a deal with the administration to rein in prices and expects United States — Medicaid discounts to result in price and margin compression next year.
Dec 19, 2025 · 7 articles
NEWSDESK
Explore this relationship live
Track how United States and Pfizer interact across events, view sentiment trends, and discover connected entities.
Open Dashboard